According to a recent study published in the journal Annals of Oncology, pediatric patients treated with ifosfamide-doxorubicin chemotherapy and radiotherapy experienced satisfactory overall results, with higher survival rates than those previously published.
For the study, researchers enrolled 138 patients <21 years old with nonmetastatic synovial sarcoma from 60 centers in 9 countries. Patients received ifosfamide plus doxorubicin in addition to radiotherapy.
Results showed that with a median follow-up of 52.1 months, the event-free survival was 81.9% and 80.7% at 3 and 5 years, respectively. In addition, the overall survival was 92.7% at 3 years and 90.7% at 5 years.
Univariate analysis showed that the 3-year event-free survival was 91.7% for low-risk patients, 91.2% for intermediate-risk patients, and 74.4% for high-risk patients.
Among 24 patients with low-risk disease who were treated with surgery alone, two experienced local relapses and there were no metastatic recurrences.
The authors conclude that the findings suggest “that collaborative prospective studies on rare pediatric sarcomas are feasible even on a European scale, with excellent treatment compliance.”